Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
Small cell lung cancer
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
Would they significantly interfere with each other? Thank you.
Related Questions
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Do you offer consolidation durvalumab in a patient who had pneumonitis requiring steroids following chemoradiation for LS-SCLC?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
In NSCLC, would you manage other MET alterations, such as a MET T618T mutation, in the same way as a MET exon 14 skipping mutation?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
What are your top takeaways in thoracic cancers from ESMO 2025?
Would you give consolidation durvalumab to a patient who underwent chemoradiation for his stage III NSCLC and is being started on antifibrotic therapy by pulmonology for his ILD?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?
How would you treat a young patient with an EGFR 19 deletion and a locally advanced lung mass who had a brain metastasis that was resected?